# Morgan Stanley maintains a Buy rating on Telix Pharmaceuticals, with a price target of A$24.60.

*business · news · 2026-04-07 · Markets Insider*

## Key points

- David Bailey from Morgan Stanley reaffirmed a Buy rating on Telix Pharmaceuticals with a A$24.60 target.
- Canaccord Genuity’s Shane Storey also issued a Buy rating on Telix Pharmaceuticals today.
- TipRanks – OpenAI reiterated a Hold rating on Telix Pharmaceuticals on March 26.
- Telix Pharmaceuticals currently has a market cap of A$4.39B and a P/E ratio of -342.48.

**Companies:** Telix Pharmaceuticals, Ramsay Health Care, Resmed
**Countries:** Australia

[Read the full story on Markets Insider](https://markets.businessinsider.com/news/stocks/morgan-stanley-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-1036002013)

---

Canonical: https://newsio.io/n/a3a76d22-0044-4432-9289-36ff44851963/morgan-stanley-maintains-a-buy-rating-on-telix-pharmaceuticals-with-a-price-targ
Summarized by Newsio from Markets Insider. https://newsio.io/how-it-works